FR11C0004I2 - Agonistes du recepteur a 2a n-pyrazole - Google Patents

Agonistes du recepteur a 2a n-pyrazole

Info

Publication number
FR11C0004I2
FR11C0004I2 FR11C0004C FR11C0004C FR11C0004I2 FR 11C0004 I2 FR11C0004 I2 FR 11C0004I2 FR 11C0004 C FR11C0004 C FR 11C0004C FR 11C0004 C FR11C0004 C FR 11C0004C FR 11C0004 I2 FR11C0004 I2 FR 11C0004I2
Authority
FR
France
Prior art keywords
pyrazole
receptor agonists
agonists
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR11C0004C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Original Assignee
CV Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Therapeutics Inc filed Critical CV Therapeutics Inc
Publication of FR11C0004I1 publication Critical patent/FR11C0004I1/fr
Application granted granted Critical
Publication of FR11C0004I2 publication Critical patent/FR11C0004I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR11C0004C 1999-06-22 2011-02-07 Agonistes du recepteur a 2a n-pyrazole Active FR11C0004I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/338,185 US6403567B1 (en) 1999-06-22 1999-06-22 N-pyrazole A2A adenosine receptor agonists
PCT/US2000/040281 WO2000078779A2 (fr) 1999-06-22 2000-06-21 Agonistes du recepteur a2a n-pyrazole

Publications (2)

Publication Number Publication Date
FR11C0004I1 FR11C0004I1 (fr) 2011-03-11
FR11C0004I2 true FR11C0004I2 (fr) 2012-03-16

Family

ID=23323763

Family Applications (1)

Application Number Title Priority Date Filing Date
FR11C0004C Active FR11C0004I2 (fr) 1999-06-22 2011-02-07 Agonistes du recepteur a 2a n-pyrazole

Country Status (27)

Country Link
US (9) US6403567B1 (fr)
EP (1) EP1189916B1 (fr)
JP (1) JP4727880B2 (fr)
KR (1) KR100463300B1 (fr)
CN (1) CN1167709C (fr)
AR (1) AR024441A1 (fr)
AT (1) ATE256141T1 (fr)
AU (1) AU760806B2 (fr)
BE (1) BE2011C004I2 (fr)
BR (1) BRPI0011856B8 (fr)
CA (1) CA2377746C (fr)
CY (1) CY2011002I1 (fr)
DE (2) DE60007127T2 (fr)
DK (1) DK1189916T3 (fr)
ES (1) ES2209974T3 (fr)
FR (1) FR11C0004I2 (fr)
HK (1) HK1044952B (fr)
IL (2) IL147198A0 (fr)
LU (1) LU91785I2 (fr)
MX (1) MXPA01013325A (fr)
NO (2) NO322457B1 (fr)
NZ (1) NZ516334A (fr)
PT (1) PT1189916E (fr)
TR (1) TR200200588T2 (fr)
TW (1) TWI230161B (fr)
WO (1) WO2000078779A2 (fr)
ZA (1) ZA200200301B (fr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47351E1 (en) * 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
CA2439222C (fr) * 2000-02-23 2009-07-14 Cv Therapeutics, Inc. Procede permettant d'identifier des agonistes partiels du recepteur a2a
US20050059068A1 (en) * 2001-05-23 2005-03-17 Stratagene California Compositions and methods using dendrimer-treated microassays
US7262176B2 (en) 2001-08-08 2007-08-28 Cv Therapeutics, Inc. Adenosine A3 receptor agonists
US20030078232A1 (en) * 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
ATE348643T1 (de) 2002-02-15 2007-01-15 Cv Therapeutics Inc Polymerüberzug für medizinische vorrichtungen
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
WO2004011010A1 (fr) * 2002-07-29 2004-02-05 Cv Therapeutics, Inc. Imagerie de perfusion myocardique au moyen d'agonistes de recepteur a2a
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
WO2004022573A2 (fr) 2002-09-09 2004-03-18 Cv Therapeutics, Inc. Agonistes du recepteur de l'adenosine a3
DK1708721T3 (da) 2004-01-27 2013-09-08 Gilead Sciences Inc Billeddannelse af myokardieperfusion under anvendelse af adenosin-receptor-agonister
TWI346109B (en) 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
US7423144B2 (en) * 2004-05-26 2008-09-09 Inotek Pharmaceuticals Corporation Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof
BRPI0515506A (pt) * 2004-09-20 2008-07-29 Inotek Pharmaceuticals Corp derivados de purina e métodos de uso dos mesmos
CA2583185A1 (fr) * 2004-10-20 2006-04-27 Cv Therapeutics, Inc. Utilisation d'agonistes du recepteur de l'adenosine a2a
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0505219D0 (en) * 2005-03-14 2005-04-20 Novartis Ag Organic compounds
JP5042996B2 (ja) * 2005-05-19 2012-10-03 ギリアード・パロ・アルト・インコーポレイテッド Ａ１アデノシンレセプターアゴニスト
BRPI0619261A2 (pt) * 2005-11-30 2011-09-27 Inotek Pharmaceuticals Corp derivados de purina e métodos de uso desses
PL1989214T3 (pl) * 2006-02-03 2017-07-31 Gilead Sciences, Inc. Proces otrzymywania agonisty receptora adenozynowego a2a i jego polimorfów
US20070183995A1 (en) * 2006-02-09 2007-08-09 Conopco, Inc., D/B/A Unilever Compounds useful as agonists of A2A adenosine receptors, cosmetic compositions with A2A agonists and a method for using the same
GB0607951D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
ATE549337T1 (de) 2006-04-21 2012-03-15 Novartis Ag Purinderivate zur verwendung als adenosin-a2a- rezeptoragonisten
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
DE102006020349A1 (de) 2006-04-28 2007-10-31 Mahle International Gmbh Kolbenmotor und zugehöriges Betriebsverfahren
US7691825B2 (en) * 2006-06-06 2010-04-06 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor agonists
CA2655310A1 (fr) * 2006-06-22 2008-05-29 Cv Therapeutics, Inc. Utilisation d'agonistes de recepteur d'adenosine a<sb>2a</sb> dans le traitement d'une ischemie
EP1889846A1 (fr) * 2006-07-13 2008-02-20 Novartis AG Dérivés de purine comme agonistes du recepteur A2a
JP2010502649A (ja) * 2006-09-01 2010-01-28 シーブイ・セラピューティクス・インコーポレイテッド 心筋層画像化法中の患者の耐性を増加させるための方法および組成物
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
EP1903044A1 (fr) * 2006-09-14 2008-03-26 Novartis AG Derivés de l'adénosine en tant qu' agonistes du récepteur A2A
JP2011502101A (ja) * 2006-09-29 2011-01-20 ギリアード・パロ・アルト・インコーポレイテッド 肺疾患の病歴を有する患者における心筋画像化法
JP2010508835A (ja) * 2006-11-10 2010-03-25 ノバルティス アーゲー シクロペンテンジオールモノアセテート誘導体
EP2099360A2 (fr) * 2007-01-03 2009-09-16 CV Therapeutics Inc. Imagerie de perfusion myocardique
WO2008133129A1 (fr) * 2007-04-16 2008-11-06 Santen Pharmaceutical Co., Ltd. Agent thérapeutique pour le glaucome renfermant un agoniste du récepteur a2a de l'adénosine en tant que principe actif
RU2443708C2 (ru) * 2007-05-17 2012-02-27 Си Ви Терапьютикс, Инк. Способ получения агониста рецептора a2a-аденозина и его полиморфных модификаций
NZ580940A (en) * 2007-05-17 2012-02-24 Gilead Palo Alto Inc Process for preparing an a2a-adenosine receptor agonist and its polymorphs
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
US7899039B2 (en) * 2008-02-15 2011-03-01 Cisco Technology, Inc. System and method for providing location and access network information support in a network environment
PL2300489T3 (pl) 2008-06-06 2016-11-30 Sposoby wytwarzania 17-alkinylo-7-hydroksysteroidów i związków pokrewnych
EP2344145A1 (fr) * 2008-09-29 2011-07-20 Gilead Sciences, Inc. Combinaisons d'agent de régulation de la fréquence cardiaque et d'antagoniste de récepteur a-2-alpha utilisées dans des procédés de tomographie à détecteurs multiples assistée par ordinateur
US7957314B2 (en) * 2008-12-12 2011-06-07 Cisco Technology, Inc. System and method for provisioning charging and policy control in a network environment
LT2523669T (lt) 2010-01-11 2017-04-25 Inotek Pharmaceuticals Corporation Akispūdžio mažinimo būdas, derinys ir rinkinys
AU2011230580A1 (en) 2010-03-26 2012-10-11 Inotek Pharmaceuticals Corporation Method of reducing intraocular pressure in humans using N6 -cyclopentyladenosine (CPA), CPA derivatives or prodrugs thereof
US20130109645A1 (en) 2010-03-31 2013-05-02 The united States of America,as represented by Secretary,Dept.,of Health and Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
US9215588B2 (en) 2010-04-30 2015-12-15 Cisco Technology, Inc. System and method for providing selective bearer security in a network environment
JP2011098990A (ja) * 2011-02-21 2011-05-19 Gilead Palo Alto Inc アデノシン受容体作動薬を使用する心筋灌流イメージング方法
US8859522B2 (en) 2011-04-27 2014-10-14 Reliable Biopharmaceutical Corporation Processes for the preparation of regadenoson and a new crystalline form thereof
CZ308577B6 (cs) 2011-08-18 2020-12-16 Farmak, A. S. Způsob přípravy 2-(4-methoxykarbonylpyrazol-1-yl)adenosinu a 2-(4-ethoxykarbonylpyrazol-1-yl)adenosinu
CZ304053B6 (cs) 2011-08-22 2013-09-04 Farmak, A. S. Zpusob prípravy 2-[4-[(methylamino)karbonyl]-1-H-pyrazol-1-yl]adenosinu monohydrátu
PL2807178T3 (pl) 2012-01-26 2017-12-29 Inotek Pharmaceuticals Corporation Bezwodne polimorfy azotanu (2R,3S,4R,5R)-5-(6-(cyklopentyloamino)-9H-puryn-9-ylo)-3,4-dihydroksytetrahydrofuran-2-ylo)metylu i sposoby ich wytwarzania
US20150290236A1 (en) * 2012-11-30 2015-10-15 Leiutis Pharmaceuticals Pvt. Ltd. Pharmaceutical compositions of regadenoson
WO2014152723A1 (fr) 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation Formulations ophtalmiques
EP2789624B1 (fr) 2013-04-11 2020-09-23 AMRI Italy S.r.l. Formes solides stables de regadenoson
CZ305213B6 (cs) 2013-04-29 2015-06-10 Farmak, A. S. Polymorf E 2-[4-[(methylamino)karbonyl]-1H-pyrazol-1-yl]adenosinu a způsob jeho přípravy
US9624258B2 (en) 2013-05-30 2017-04-18 Biophore India Pharmaceuticals Pvt. Ltd. Polymorph of regadenoson
CN104513241B (zh) * 2013-09-30 2017-02-08 浙江海正药业股份有限公司 瑞加德松新中间体及其制备方法和应用
CN104744540A (zh) * 2013-12-26 2015-07-01 上海紫源制药有限公司 一种制备瑞加德松的方法
CN105085593A (zh) * 2014-04-21 2015-11-25 上海紫源制药有限公司 瑞加德松的晶型及其制备方法
US10442832B2 (en) 2015-02-06 2019-10-15 Apicore Us Llc Process of making regadenoson and novel polymorph thereof
US9809617B2 (en) 2015-07-03 2017-11-07 Shanghai Ziyuan Pharmaceutical Co., Ltd. Crystal form of regadenoson and preparation method thereof
CN106397442B (zh) * 2015-07-28 2020-03-27 国药集团国瑞药业有限公司 一种瑞加德松的纯化方法
RU2742417C1 (ru) 2017-01-13 2021-02-05 Тобиси Фармасьютикал Ко., Лтд. Регулятор активации нейтрофилов
WO2019191389A1 (fr) 2018-03-29 2019-10-03 Johnson Matthey Public Limited Company Formes à l'état solide de régadénoson, leur utilisation et leur préparation
US10815265B2 (en) 2018-06-29 2020-10-27 Usv Private Limited Process for preparation of regadenoson and polymorphs thereof
WO2025257365A1 (fr) 2024-06-14 2025-12-18 Institut National de la Santé et de la Recherche Médicale Antagonistes de l'adénosine a2a pour le traitement de l'endométriose

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK135130B (da) 1970-12-28 1977-03-07 Takeda Chemical Industries Ltd Analogifremgangsmåde til fremstilling af 2-substituerede adenosinderivater eller syreadditionssalte deraf.
BE787064A (fr) 1971-08-03 1973-02-01 Philips Nv Dispositif magnetique comportant des domaines
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4089959A (en) * 1976-03-31 1978-05-16 Cooper Laboratories, Inc. Long-acting xanthine bronchodilators and antiallergy agents
US4120947A (en) * 1976-03-31 1978-10-17 Cooper Laboratories, Inc. Xanthine compounds and method of treating bronchospastic and allergic diseases
SE7810946L (sv) * 1978-10-20 1980-04-21 Draco Ab Metod att behandla kronisk obstruktiv luftvegssjukdom
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4696932A (en) * 1984-10-26 1987-09-29 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active xanthine derivatives
JPS6299395A (ja) 1985-10-25 1987-05-08 Yamasa Shoyu Co Ltd ２−アルキニルアデノシンおよび抗高血圧剤
US4968697A (en) * 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) * 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4990498A (en) * 1988-04-26 1991-02-05 Temple University-Of The Commonwealth System Of Higher Education 2- and 8-azido(2'-5')oligoadenylates and antiviral uses thereof
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5070877A (en) 1988-08-11 1991-12-10 Medco Research, Inc. Novel method of myocardial imaging
DE3831430A1 (de) * 1988-09-15 1990-03-22 Bayer Ag Substituierte 4-heterocyclyloximino-pyrazolin-5-one, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
DE68916036T2 (de) 1988-11-15 1994-09-29 Toa Eiyo Ltd Mittel zur behandlung und prophylaxe koronarer und zerebraler ischämischer erkrankungen.
IT1229195B (it) 1989-03-10 1991-07-25 Poli Ind Chimica Spa Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche.
KR920700218A (ko) 1989-06-20 1992-02-19 원본미기재 2-알키닐 아데노신의 합성중간체, 그 합성 중간체의 제조법, 그 합성중간체를 이용한 2-알키닐 아데노신의 제조법 및 안정한 2-알키닐 아데노신 유도체
US5032252A (en) * 1990-04-27 1991-07-16 Mobil Oil Corporation Process and apparatus for hot catalyst stripping in a bubbling bed catalyst regenerator
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5189027A (en) 1990-11-30 1993-02-23 Yamasa Shoyu Kabushiki Kaisha 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases
FR2671356B1 (fr) 1991-01-09 1993-04-30 Inst Nat Sante Rech Med Procede de description des repertoires d'anticorps (ab) et des recepteurs des cellules t (tcr) du systeme immunitaire d'un individu.
JP2740362B2 (ja) 1991-02-12 1998-04-15 ヤマサ醤油株式会社 安定な固体状２‐オクチニルアデノシンおよびその製造法
JP3053908B2 (ja) 1991-06-28 2000-06-19 ヤマサ醤油株式会社 ２‐アルキニルアデノシン誘導体
US5516894A (en) * 1992-03-11 1996-05-14 The General Hospital Corporation A2b -adenosine receptors
IT1254915B (it) 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
GB9210839D0 (en) 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
WO1993025677A1 (fr) 1992-06-12 1993-12-23 Garvan Institute Of Medical Research SEQUENCES D'ADN CODANT LES RECEPTEURS HUMAINS DE L'ADENOSINE A1, A2a ET A2b
EP0601322A3 (fr) 1992-10-27 1994-10-12 Nippon Zoki Pharmaceutical Co Inhibiteur de déaminase d'adénosine.
CA2112031A1 (fr) * 1992-12-24 1994-06-25 Fumio Suzuki Derives xanthine
US5477857A (en) 1993-09-10 1995-12-26 Discovery Therapeutics, Inc. Diagnostic uses of hydrazinoadenosines
WO1995011681A1 (fr) 1993-10-29 1995-05-04 Merck & Co., Inc. Antagonistes du recepteur de l'adenosine humaine
DE69526822T2 (de) * 1994-02-23 2003-01-23 Kyowa Hakko Kogyo K.K., Tokio/Tokyo Xanthin-derivate
US5704491A (en) * 1995-07-21 1998-01-06 Cummins-Allison Corp. Method and apparatus for discriminating and counting documents
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US6448235B1 (en) * 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
US6514949B1 (en) * 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US5854081A (en) * 1996-06-20 1998-12-29 The University Of Patent Foundation Stable expression of human A2B adenosine receptors, and assays employing the same
US5780481A (en) * 1996-08-08 1998-07-14 Merck & Co., Inc. Method for inhibiting activation of the human A3 adenosine receptor to treat asthma
US5776960A (en) * 1996-10-16 1998-07-07 Buckman Laboratories International, Inc. Synergistic antimicrobial compositions containing an ionene polymer and a pyrithione salt and methods of using the same
US5770716A (en) 1997-04-10 1998-06-23 The Perkin-Elmer Corporation Substituted propargylethoxyamido nucleosides, oligonucleotides and methods for using same
WO1998052611A1 (fr) 1997-05-23 1998-11-26 Nippon Shinyaku Co., Ltd. Preparation medicamenteuse aux fins de la prevention et du traitement des hepatopathies
AU740770B2 (en) 1997-06-18 2001-11-15 Aderis Pharmaceuticals, Inc. Compositions and methods for preventing restenosis following revascularization procedures
US6026317A (en) 1998-02-06 2000-02-15 Baylor College Of Medicine Myocardial perfusion imaging during coronary vasodilation with selective adenosine A2 receptor agonists
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
AU4675699A (en) 1998-06-08 1999-12-30 Epigenesis Pharmaceuticals, Inc. Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs
US6322771B1 (en) * 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
AU760071B2 (en) 1999-08-31 2003-05-08 Vanderbilt University Selective antagonists of A2B adenosine receptors
US6368573B1 (en) * 1999-11-15 2002-04-09 King Pharmaceuticals Research And Development, Inc. Diagnostic uses of 2-substituted adenosine carboxamides
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
US6677336B2 (en) * 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
US6552023B2 (en) * 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
CA2439222C (fr) * 2000-02-23 2009-07-14 Cv Therapeutics, Inc. Procede permettant d'identifier des agonistes partiels du recepteur a2a
US6387913B1 (en) * 2000-12-07 2002-05-14 S. Jamal Mustafa Method of treating airway diseases with combined administration of A2B and A3 adenosine receptor antagonists
US6670334B2 (en) * 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
US6995148B2 (en) * 2001-04-05 2006-02-07 University Of Pittsburgh Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy
US6599283B1 (en) * 2001-05-04 2003-07-29 Cv Therapeutics, Inc. Method of preventing reperfusion injury
US7109203B2 (en) * 2001-05-14 2006-09-19 Novartis Ag Sulfonamide derivatives
KR100937620B1 (ko) * 2001-11-09 2010-01-20 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ２ｂ 아데노신 수용체 길항제
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
BR0215202A (pt) * 2001-12-20 2004-10-13 Osi Pharm Inc Compostos antagonistas seletivos a2b de pirimidina, sua sìntese e uso
WO2003086451A1 (fr) * 2002-04-05 2003-10-23 Centocor, Inc. Proteines derivees de l'immunoglobuline anti il-13 associees a l'asthme, compositions, procedes et utilisations associes
CN101385738A (zh) 2002-04-18 2009-03-18 Cv医药有限公司 包括给予A1腺苷激动剂以及β受体阻滞剂、钙通道阻滞剂、或强心苷的治疗心律失常的方法
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
WO2004011010A1 (fr) * 2002-07-29 2004-02-05 Cv Therapeutics, Inc. Imagerie de perfusion myocardique au moyen d'agonistes de recepteur a2a
DK1708721T3 (da) 2004-01-27 2013-09-08 Gilead Sciences Inc Billeddannelse af myokardieperfusion under anvendelse af adenosin-receptor-agonister
AU2005295654B2 (en) * 2004-10-15 2011-04-14 Gilead Sciences, Inc. Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
CA2583185A1 (fr) * 2004-10-20 2006-04-27 Cv Therapeutics, Inc. Utilisation d'agonistes du recepteur de l'adenosine a2a
BRPI0606662A2 (pt) * 2005-01-12 2010-02-09 King Pharmaceuticals Res & Dev métodos para diagnosticar a disfunção miocárdica, a doença da artéria coronária, a disfunção ventricular causada pela doença da artéria coronária, anormalidades de perfusão, para diagnosticar a presença e avaliar a severidade da doença da artéria coronária e a severidade da disfunção ventricular e a disfunção miocárdica, e, kit
PL1989214T3 (pl) * 2006-02-03 2017-07-31 Gilead Sciences, Inc. Proces otrzymywania agonisty receptora adenozynowego a2a i jego polimorfów
CA2655310A1 (fr) 2006-06-22 2008-05-29 Cv Therapeutics, Inc. Utilisation d'agonistes de recepteur d'adenosine a<sb>2a</sb> dans le traitement d'une ischemie
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
JP2010502649A (ja) * 2006-09-01 2010-01-28 シーブイ・セラピューティクス・インコーポレイテッド 心筋層画像化法中の患者の耐性を増加させるための方法および組成物
JP2011502101A (ja) * 2006-09-29 2011-01-20 ギリアード・パロ・アルト・インコーポレイテッド 肺疾患の病歴を有する患者における心筋画像化法
EP2099360A2 (fr) * 2007-01-03 2009-09-16 CV Therapeutics Inc. Imagerie de perfusion myocardique
NZ580940A (en) 2007-05-17 2012-02-24 Gilead Palo Alto Inc Process for preparing an a2a-adenosine receptor agonist and its polymorphs
WO2009076580A2 (fr) 2007-12-12 2009-06-18 Thomas Jefferson University Compositions et procédés pour le traitement et la prévention de maladies cardiovasculaires
EP2344145A1 (fr) * 2008-09-29 2011-07-20 Gilead Sciences, Inc. Combinaisons d'agent de régulation de la fréquence cardiaque et d'antagoniste de récepteur a-2-alpha utilisées dans des procédés de tomographie à détecteurs multiples assistée par ordinateur

Also Published As

Publication number Publication date
US20110144320A1 (en) 2011-06-16
BR0011856A (pt) 2004-02-10
FR11C0004I1 (fr) 2011-03-11
ATE256141T1 (de) 2003-12-15
US20130058866A1 (en) 2013-03-07
CA2377746C (fr) 2007-04-10
DE60007127T2 (de) 2004-09-16
EP1189916A2 (fr) 2002-03-27
LU91785I2 (fr) 2011-03-31
US7655637B2 (en) 2010-02-02
US7144872B2 (en) 2006-12-05
BE2011C004I2 (fr) 2019-05-21
IL147198A0 (en) 2002-08-14
TWI230161B (en) 2005-04-01
NO20016350D0 (no) 2001-12-21
AU7132400A (en) 2001-01-09
BRPI0011856B8 (pt) 2021-05-25
ES2209974T3 (es) 2004-07-01
IL147198A (en) 2006-04-10
US20100160620A1 (en) 2010-06-24
US20140073596A1 (en) 2014-03-13
BR0011856B1 (pt) 2014-06-17
AU760806B2 (en) 2003-05-22
CA2377746A1 (fr) 2000-12-28
CY2011002I2 (el) 2012-01-25
PT1189916E (pt) 2004-03-31
NO322457B1 (no) 2006-10-09
NZ516334A (en) 2004-05-28
US9045519B2 (en) 2015-06-02
DK1189916T3 (da) 2004-03-22
KR100463300B1 (ko) 2004-12-23
US8569260B2 (en) 2013-10-29
AR024441A1 (es) 2002-10-02
US6403567B1 (en) 2002-06-11
EP1189916B1 (fr) 2003-12-10
CY2011002I1 (el) 2012-01-25
NO20016350L (no) 2002-02-18
CN1358191A (zh) 2002-07-10
US20070203090A1 (en) 2007-08-30
NO2011002I1 (no) 2011-03-07
HK1044952A1 (en) 2002-11-08
ZA200200301B (en) 2003-11-26
TR200200588T2 (tr) 2002-09-23
NO2011002I2 (no) 2012-10-22
US20060052332A1 (en) 2006-03-09
DE60007127D1 (de) 2004-01-22
US8278435B2 (en) 2012-10-02
HK1044952B (zh) 2005-02-25
US7183264B2 (en) 2007-02-27
JP4727880B2 (ja) 2011-07-20
JP2003506461A (ja) 2003-02-18
MXPA01013325A (es) 2002-07-02
WO2000078779A2 (fr) 2000-12-28
WO2000078779A3 (fr) 2001-03-15
US6642210B1 (en) 2003-11-04
CN1167709C (zh) 2004-09-22
US20040038928A1 (en) 2004-02-26
KR20020028910A (ko) 2002-04-17
DE122011000010I1 (de) 2011-06-16

Similar Documents

Publication Publication Date Title
FR11C0004I1 (fr) Agonistes du recepteur a 2a n-pyrazole
FR10C0006I2 (fr) Agonistes du recepteur beta 2-adrenergique
MA25403A1 (fr) Ligandes de recepteur de melanocortine
EP1019360A4 (fr) AGONISTES DU RECEPTEUR $g(b)2-ADRENERGIQUE
DK1446379T3 (da) Arylanilin-beta2-adrenergiske receptoragonister
DE60026169D1 (de) Selektive neurokinin-antagonisten
PT1192169E (pt) C-pirazoles agonistas do receptor a2a
DE60132799D1 (de) Peroxisom proliferator aktivierten rezeptor alpha agonisten
NO20012450D0 (no) Holdesegment for svivelanordning
EP0880511A4 (fr) Antagonistes du recepteur integrine
NO993131L (no) Svivelinnretning
NO20013997L (no) Reseptoranalyse
NO20016053D0 (no) IL-8 reseptor-antagonister
NO20024193L (no) IL-8 reseptorantagonister
NO20016052L (no) IL-8-reseptor-antagonister
MA25265A1 (fr) Antagoniste du recepteur de vitronectime.
DE60033145D1 (de) Il-8 rezeptorantagonist
EP1213621A4 (fr) Dispositif de developpement
EP1239033A4 (fr) Recepteur de semaphorine
NO20015774D0 (no) IL-8 reseptorantagonister
EP1233981A4 (fr) Recepteur couple a la proteine g
NO20021113D0 (no) Vitronectin-reseptor-antagonister
EP1189944A4 (fr) Axor16, r cepteur coupl une prot ine g
NO20021295D0 (no) Nikotinsyreacetylcholin-reseptor
NO995727L (no) Bæreanordning